Themis Medicare Ltd
Company Profile
Business description
Themis Medicare Ltd is principally engaged in manufacturing pharmaceutical products, including finished formulations and synthetic Active Pharmaceutical Ingredients (APIs). Its formulation products cover therapy areas such as analgesics and anti-inflammatory, anesthesia, anti-fungal, anti-biotic, anti-diabetic, and anti-emetic products, available in forms including tablets, injections, gels, capsules, syrups, and suspensions. Its business is structured across Hospital Business, Trade Business and API Business. The Company operates in one segment, Pharmaceuticals, and operates in India, which generates the maximum revenue, as well as outside India.
Contact
Swami Vivekanand Road
11/12, Udyog Nagar Industrial Estate
Goregaon (West)
MumbaiMH400 104
INDT: +91 2267607080
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
1,696
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |